학술논문
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open label, randomised, multicentre phase 2 trial.
Document Type
Article
Author
Kwo, Paul Y.; Lawitz, Eric J.; McCone, Jonathan; Schiff, Eugene R.; Vierling, John M.; Pound, David; Davis, Mitcheil N.; Galati, Joseph S.; Gordon, Stuart C.; Ravendhran, Natarajan; Rossaro, Lorenzo; Anderson, Frank H.; Jacobson, Ira M.; Rubin, Raymond; Koury, Kenneth; Pedicone, Lisa D.; Brass, Clifford A.; Chaudhri, Eirum; Albrecht, Janice K.
Source
Subject
*RIBAVIRIN
*HEPATITIS C treatment
*PROTEASE inhibitors
*MEDICAL research
*MEDICAL sciences
*PATIENTS
*
*
*
*
*
Language
ISSN
0140-6736
Abstract
The article presents a research which analyzes the efficacy of boceprevir in combination with peginterferon alfa-2b and ribavirin for the treatment of patients suffering from genotype 1 hepatitis C infection. It is reported that, boceprevir is an NS3 protease inhibitor, and researchers carried out the test by treating the patients with the combination of boceprevir, peginterferon, and ribavirin, for 48 weeks at 67 sites in the U.S. Canada, and Europe. Researchers conclude that, with the addition of boceprevir, it was found that sustained response rate of the patients doubled as compared to treatment with only peginterferon and ribavirin.